Correlation between Serum Levels of Anti-HBC，CHE，and Apolipoprotein AI and the Development of Viral Hepatitis

Su XU; Yuqing LIU; Xingwang ZHENG

Article Contents

Article Navigation > Journal of Kunming Medical University > 2024 >

Su XU, Yuqing LIU, Xingwang ZHENG. Correlation between Serum Levels of Anti-HBC，CHE，and Apolipoprotein AI and the Development of Viral Hepatitis[J]. Journal of Kunming Medical University.

Citation:

Su XU, Yuqing LIU, Xingwang ZHENG. Correlation between Serum Levels of Anti-HBC，CHE，and Apolipoprotein AI and the Development of Viral Hepatitis[J]. Journal of Kunming Medical University.

Su XU, Yuqing LIU, Xingwang ZHENG. Correlation between Serum Levels of Anti-HBC，CHE，and Apolipoprotein AI and the Development of Viral Hepatitis[J]. Journal of Kunming Medical University.

Citation:

Su XU, Yuqing LIU, Xingwang ZHENG. Correlation between Serum Levels of Anti-HBC，CHE，and Apolipoprotein AI and the Development of Viral Hepatitis[J]. Journal of Kunming Medical University.

PDF( 592 KB)

Correlation between Serum Levels of Anti-HBC，CHE，and Apolipoprotein AI and the Development of Viral Hepatitis

1.
Clinical Laboratory，Nanjing Pukou District Hospital of Traditional Chinese Medicine，Nanjing Jiangsu 211800
2.
Clinical Laboratory，Affiliated Hospital of Nantong University，Nantong Jiangsu 226001，China

Received Date: 2024-05-09
Available Online: 2024-11-23

Abstract

Abstract

Objective To investigate the correlation between serum hepatitis B core anbody （anti-HBC）, cholinesterase （CHE） and apolipoprotein AI （ApoAI） and the development of viral hepatitis. Methods 388 patients with viral hepatitis admitted to Nanjing Pukou District Hospital of Traditional Chinese Medicine from January 2021 to January 2024 were selected as the observation group, another 68 cases of health check-ups in medical check-up centre of Nanjing Pukou District Hospital of Traditional Chinese Medicine during the same period were selected as the control group. The serum levels of anti-HBC, CHE, and apolipoprotein AI between the observation group and the control group were compared. To compare the serum anti-HBC, CHE, ApoAI levels in patients with different disease severity of chronic hepatitis in the observation group. To compare the number of positive cases of serum anti-HBC, CHE, ApoAI in patients with different disease types in the observation group. To compare the serum anti-HBC, CHE, ApoAI levels in patients with different grades of cirrhosis in the observation group. Results Serum anti-HBC levels （4.52±0.63） log10PEIU/mL were higher in the observation group than in the control group （1.12±0.26） log10PEIU/mL, and the differences were statistically significant （t = -43.822, P < 0.001） , while CHE （4.09±0.91） kU/L, ApoAI （102.54±5.95） mg/dL were lower than the control group（10.65±1.73） kU/L, （120.17±6.06） mg/dL, and the differences were statistically significant （t = 46.580, 22.477, P < 0.001）; differences in serum anti-HBC, CHE, and ApoAI levels among patients with different severity of chronic hepatitis in the observation group were statistically significant（P < 0.05）, and the serum levels of anti-HBC levels showed mild chronic hepatitis < moderate chronic hepatitis < severe chronic hepatitis, while the levels of CHE and ApoAI showed mild chronic hepatitis > moderate chronic hepatitis > severe chronic hepatitis the difference was statistically significant （P < 0.05）; the number of positive cases of serum anti-HBC, CHE, ApoAI in acute jaundiced hepatitis, severe chronic hepatitis, cirrhosis and hepatocellular carcinoma were significantly higher than those of chronic hepatitis in mild and moderate forms and the difference was statistically significant （P < 0.05）. The differences in serum anti-HBC, CHE, and ApoAI levels in patients with different grades of cirrhosis in the observation group were statistically significant （P < 0.05） and serum levels of anti-HBC levels increased continuously with the progression of the disease, whereas CHE and ApoAI decreased continuously with the difference being statistically significant （P < 0.05）. Conclusion The levels of serum anti-HBC in patients with viral hepatitis are significantly increased, while the levels of CHE and apolipoprotein AI are significantly decreased, and the levels of serum anti-HBC, CHE and apolipoprotein AI are related to the development of the disease, which contributes to the development of the disease.
- Viral hepatitis,
- Hepatitis B core anbody,
- Cholinesterase,
- Apolipoprotein

FullText(HTML)

References(27)

References

[1]	Ortiz B L,Navarro E K,Rodríguez M A,et al. Occult hepatitis B virus infection in hepatic diseases and its significance for the WHO’s elimination plan of viral hepatitis[J]. Pathogens,2024,13(8):662-662.
[2]	August M O,Sonali P. Viral hepatitis: Past,present,and future[J]. World Journal of Gastroenterology,2022,28(14):1405-1429. doi: 10.3748/wjg.v28.i14.1405
[3]	李小侠. 血清谷氨酸脱氢酶与其他肝功能指标联合检测在肝病诊断中的临床意义[J]. 陕西医学杂志,2020,49(12):1677-1680.
[4]	刘书宏,梁尘格,向毅,等. 慢性乙型肝炎患者血清白介素17A和胆碱酯酶的表达及临床意义[J]. 现代生物医学进展,2019,19(20):3959-3962.
[5]	于德敏,张欣欣. 血清HBsAg定量检测在慢性乙型肝炎临床诊疗中的应用及其意义[J]. 临床肝胆病杂志,2019,35(10):2150-2155.
[6]	高颖. 载脂蛋白AI和B在脂肪肝中的调节作用[J]. 安徽农业科学,2020,48(12):86-87.
[7]	中华医学会健康管理学分会, 中华医学会肝病学分会, 中华医学会检验医学分会. 病毒性肝炎健康管理专家共识(2021年)[J]. 中华健康管理学杂志,2021,15(4):323-331.
[8]	谢诗桐. 基于方法对比的中国一般人群健康效用积分体系构建研究—以六维健康调查简表第二版(SF-6Dv2)为例 [D]. 天津: 天津大学, 2020.
[9]	赵晓岚,杨颖楠,李晓. 不同Child-Pugh分级肝硬化患者凝血功能指标变化的临床意义[J]. 微量元素与健康研究,2024,41(2):15-16.
[10]	李飞飞,张春阳. 慢性乙型病毒性肝炎肝硬化患者病情严重程度及预后研究[J]. 实用医技杂志,2024,31(7):493-497.
[11]	张云颖,关霞,任小平. 病毒性肝炎-肝硬化-原发性肝癌病因形态学及防治策略的研究进展[J]. 癌症进展,2021,19(17):1745-1748.
[12]	管仲阳,孙立信,祁耀. 2005—2020年盐城市丙型病毒性肝炎的流行病学特征分析[J]. 现代预防医学,2022,49(7):1181-1184,1216.
[13]	Baudi I,Inoue T,Tanaka Y. Novel biomarkers of hepatitis B and hepatocellular carcinoma: Clinical significance of HBcrAg and M2BPGi[J]. Int J Mol Sci,2020,21(3):949. doi: 10.3390/ijms21030949
[14]	胡海石,董博,王德景,等. 乙型肝炎病毒大蛋白检测在慢性乙型肝炎诊疗中的临床意义[J]. 中西医结合肝病杂志,2020,30(3):205-207.
[15]	徐尧,冯静云,郑立明,等. 失代偿期肝硬化合并腹腔感染患者的临床特征及预后影响因素分析[J]. 中国感染与化疗杂志,2023,23(3):313-317.
[16]	刘天晨,徐华,雷宇,等. 新型口服抗凝剂和传统抗凝剂在需要抗凝治疗的肝硬化患者中的疗效与安全性比较[J]. 中华肝脏病杂志,2022,30(6):598-605.
[17]	渠畅. 肝硬化患者血清脂类及载脂蛋白变化的临床意义 [D]. 济南: 山东大学,2020.
[18]	施国美,祝忠良. 常见生化检测指标在原发性胆汁性肝硬化中的临床意义[J]. 中国卫生检验杂志,2020,30(11):1320-1321.
[19]	赵伟,陈艳清,季媛媛,等. 早期诊断急性乙型肝炎的新指标: 抗HBc-IgM/HBV DNA定量log值[J]. 肝脏,2022,27(6):655-657.
[20]	高晓霞,胡晓波. 生化免疫指标检测在乙型肝炎病情预判中的准确性及临床意义[J]. 陕西中医,2021,42(S01):17-18.
[21]	张欢,李小安,刘华柱,等. 血清PA ChE和TBA水平与肝硬化门静脉高压伴上消化道出血的关系[J]. 河北医学,2022,28(1):47-51.
[22]	杨建波,石睿,马欢,等. 肝硬化患者血清前白蛋白,血清胆碱酯酶和总胆汁酸水平检测的临床意义[J]. 西部医学,2022,34(7):1006-1010.
[23]	卢燕辉,徐成润,卢秋燕,等. 乙型肝炎病毒与载脂蛋白B关系及其意义的实验研究[J]. 中国临床研究,2019,32(1):39-42.
[24]	常凤霞,马晓莉,毛迪,等. 慢性丙型肝炎患者载脂蛋白L1基因突变检测[J]. 长春中医药大学学报,2021,37(1):123-125.
[25]	徐飞,汪光海,邱伟. 肝癌手术前后血清甲胎蛋白和白蛋白及载脂蛋白水平的变化及意义[J]. 中国肿瘤临床与康复,2021,28(9):1107-1110.
[26]	孔玉萍,朱素楠,魏明慧. 血脂、载脂蛋白及凝血功能与慢性病毒性肝炎肝组织纤维化程度的相关性研究[J]. 四川生理科学杂志,2024,46(5):1014-1016,1052.
[27]	张映华, 古晓娟. CHE、ALB、CHO在肝炎肝硬化患者中的表达及诊断效能影响研究[J]. 标记免疫分析与临床,2020,27(3):497-501.

Relative Articles(20)

Relative Articles

[1]	Lingjun SHEN, Longfen LI, Chunjing SHI, Wenming LI, Yuanqing HUANG, Huajie ZHANG, Yun LUO, jie LI, Li LIU. Factors Influencing the Development of Extra-Pulmonary Tuberculosis in Patients with Viral Hepatitis Complicated by Pulmonary Tuberculosis. Journal of Kunming Medical University,
[2]	Yanli MA, Cheng FENG, Liqing GUO, Xia GUO, Fengqiong ZHOU, Zhi-hui LIU, Yunhong MA. Application Value of Focused Solution Mode Nursing Intervention in Treatment Compliance and Quality of Life of Patients with Hepatitis C. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20230212
[3]	Baoli BAI, Xiaolin KUANG, Mingfen HU, Guoji CHANG, Lu ZHANG, Shenghao LI, Qingqing WANG. Rare Cases of Hepatitis B Virus Infection Combined with Severe Cholinesterase Deficiency not Caused by Liver Dysfunction: Two Case Reports and Literature Review. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20231210
[4]	Zhiying LU, Meifen WANG, Junchao PENG, Zengqing DU, Yunjiao LUO, Wei MA. Comparison of Serum PCT, IL-6, SAA Levels and Clinical Characteristics between Rotavirus and Norovirus Enteritis in Children. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20220823
[5]	Yun-song XUE, Li-li LI, Qian FENG, Yi-zheng LI, Lin-hua ZHOU, Jin-yi GU, Jian-mei LIU. Evaluation of Analysis Performance of Automatic Biochemical Analyzer in Detecting Serum Lipoprotein A. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20210312
[6]	Jing TANG, Jun-chao HUANG, Ya-fei HUANG, Ming-zhu GENG, Xiao-qin MAO, Jian-ping PU. Application of Lipoprotein-associated Phospholipase A2 in Coronary Heart Disease Patients Taking Statins. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20211205
[7]	Sheng-hao LI, Jie DING, Qing-qing WANG, Si-qi LIU, Li-juan HUA, Jin-yu DUAN, Bao-li BO, An-rui DU, Guo-ji CHANG, Jun-yi LI. Influencing Factors of Moderate to Severe Liver Injury in Patients with Chronic Hepatitis B and NAFLD. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20210712
[8]	Li-jia ZHU, Xiao-dan MA, Jiang DUAN, Meng LI, Yong-kun HUANG. Difference Analysis of First Liver Function Indexes of Newborns with Different Gestational Age and Birth Weight. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20210330
[9]	Lv Song Qin , Huang Shan , Li Xiao Fei , Shi Jin Li , Li Guang Min , Duan Hong Fen . Application of T-lymphocyte Subsets for Non-viral Liver Disease. Journal of Kunming Medical University,
[10]	Lu Die Qing . Association Analysis between Genetic Polymorphisms of CYP4A11, Apolipoprotein B and E Genes and Essential Hypertension Susceptibility. Journal of Kunming Medical University,
[11]	Liu Jian Hong , Zhou Ji Bo . . Journal of Kunming Medical University,
[12]	Luo Yang . Curative Effect of Tanreqing Injection Combined with Ganciclovir in the Treatment of Pediatric Respiratory Syncytial Virus Pneumonia. Journal of Kunming Medical University,
[13]	Sun Yue , Wei Jia , Lu Yong Ping , Wang Jin , Zou Yu , Wang Yu Xue , Yang Mi . Quantitative Analysis on Staging of Chronic Viral Hepatitis B and Hepatic Fibrosis by Real-time Shear Wave Elastography. Journal of Kunming Medical University,
[14]	Wang Dan . . Journal of Kunming Medical University,
[15]	Bian Hai Xia . . Journal of Kunming Medical University,
[16]	Ma Yan Li . . Journal of Kunming Medical University,
[17]	Liu Ju Peng . . Journal of Kunming Medical University,
[18]	Mu Yun Zhen . . Journal of Kunming Medical University,
[19]	. . Journal of Kunming Medical University,
[20]	. . Journal of Kunming Medical University,